Table 1 summarizes the current PARPi that are in clinical trials in NSCLC [84,85,86,87]. Recently, Marzio et al. demonstrated the role of Klech-like ECH-associated protein 1 (KEAP1) mutation, which is an important redox hemostasis regulator, in producing BRCAness phenotype in NSCLC [88]. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.